Join Saniona for a virtual R&D Day featuring key opinion leader (KOL) Nicola Specchio, MD, PhD (Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy), a globally recognized expert and principal investigator on multiple trials in pediatric epilepsy, who will join company management to discuss the significant unmet need and current treatment landscape for severe pediatric epilepsies, including Developmental Epileptic Encephalopathies (DEEs). These syndromes are often highly drug-resistant, associated with substantial seizure burden and developmental impairment, and can have lifelong consequences for patients and families.

As the first in a series of webinars designed to provide a focused overview of Saniona’s differentiated CNS pipeline, this initial event will highlight SAN2668, an oral, selective GABA_A positive allosteric modulator, and will review the rationale for targeting GABA_A, key preclinical data supporting SAN2668, the proposed Phase 1 clinical development path, and the broader disease landscape and market opportunity.

A live question and answer session will follow the formal presentations.